Details of the Drug

General Information of Drug (ID: DM3WKQ4)

Drug Name

Rasagiline

Synonyms

RAS; Rasagiline [INN]; Azilect (TN); Rasagiline (INN); (1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine; (1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine; (R)-N-2-Propynyl-1-indanamine; 1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R)

Indication

Disease Entry	ICD 11	Status	REF
Parkinson disease	8A00.0	Approved	[1], [2]
Skin cancer	2C30-2C37	Patented	[3]
Skin imperfections	EK71	Patented	[3]

Therapeutic Class

Antiparkinson Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

171.24

Topological Polar Surface Area (xlogp)

1.8

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Bioavailability: The bioavailability of drug is 36% [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 3 hours [5]
Metabolism: The drug is metabolized via the liver [4]
Vd: The volume of distribution (Vd) of drug is 87 L [6]

Chemical Identifiers

Formula: C12H13N
IUPAC Name: (1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine
Canonical SMILES: C#CCN[C@@H]1CCC2=CC=CC=C12
InChI: InChI=1S/C12H13N/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12/h1,3-6,12-13H,7-9H2/t12-/m1/s1
InChIKey: RUOKEQAAGRXIBM-GFCCVEGCSA-N

Cross-matching ID

PubChem CID: 3052776
ChEBI ID: CHEBI:63620
CAS Number: 136236-51-6
DrugBank ID: DB01367
TTD ID: D06OMW
INTEDE ID: DR1397
ACDINA ID: D00585

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Monoamine oxidase type B (MAO-B)	TTGP7BY	AOFB_HUMAN	Inhibitor	[7]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 1A2 (CYP1A2)_{Main DME}	DEJGDUW	CP1A2_HUMAN	Substrate	[8]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Parkinson disease

ICD Disease Classification

8A00.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Monoamine oxidase type B (MAO-B)	DTT	MAOB	2.65E-02	1.12E-02	0.07
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	7.36E-01	1.62E-02	1.08E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Rasagiline (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Major	Additive serotonergic effects by the combination of Rasagiline and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[29]
Amyl nitrite	DMJKO05	Moderate	Additive hypotensive effects by the combination of Rasagiline and Amyl nitrite.	Angina pectoris [BA40]	[30]
Levalbuterol	DM5YBO1	Moderate	Additive hypertensive effects by the combination of Rasagiline and Levalbuterol.	Asthma [CA23]	[31]
Obeticholic acid	DM3Q1SM	Moderate	Decreased metabolism of Rasagiline caused by Obeticholic acid mediated inhibition of CYP450 enzyme.	Autoimmune liver disease [DB96]	[32]
Olodaterol	DM62B78	Moderate	Additive hypertensive effects by the combination of Rasagiline and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[33]
Vilanterol	DMF5EK1	Moderate	Additive hypertensive effects by the combination of Rasagiline and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[31]
Indacaterol	DMQJHR7	Moderate	Additive hypertensive effects by the combination of Rasagiline and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[33]
Levomilnacipran	DMV26S8	Major	Additive serotonergic effects by the combination of Rasagiline and Levomilnacipran.	Chronic pain [MG30]	[34]
Osilodrostat	DMIJC9X	Major	Decreased metabolism of Rasagiline caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[32]
Cyclandelate	DMO0R76	Moderate	Additive hypotensive effects by the combination of Rasagiline and Cyclandelate.	Dementia [6D80-6D8Z]	[30]
Vilazodone	DM4LECQ	Major	Additive serotonergic effects by the combination of Rasagiline and Vilazodone.	Depression [6A70-6A7Z]	[34]
Vortioxetine	DM6F1PU	Major	Additive serotonergic effects by the combination of Rasagiline and Vortioxetine.	Depression [6A70-6A7Z]	[35]
Milnacipran	DMBFE74	Major	Additive serotonergic effects by the combination of Rasagiline and Milnacipran.	Depression [6A70-6A7Z]	[34]
Desvenlafaxine	DMHD4PE	Major	Additive serotonergic effects by the combination of Rasagiline and Desvenlafaxine.	Depression [6A70-6A7Z]	[34]
Esketamine	DMVU687	Major	Additive hypertensive effects by the combination of Rasagiline and Esketamine.	Depression [6A70-6A7Z]	[32]
5-hydroxy-L-tryptophan	DMDWZGJ	Major	Additive serotonergic effects by the combination of Rasagiline and 5-hydroxy-L-tryptophan.	Discovery agent [N.A.]	[36]
LEVONORDEFRIN	DMWDJ0H	Moderate	Additive hypertensive effects by the combination of Rasagiline and LEVONORDEFRIN.	Discovery agent [N.A.]	[37]
Tetrabenazine	DMYWQ0O	Major	Additive hypertensive effects by the combination of Rasagiline and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[38]
Deutetrabenazine	DMUPFLI	Major	Additive hypertensive effects by the combination of Rasagiline and Deutetrabenazine.	Dystonic disorder [8A02]	[38]
Tetrahydrozoline	DMT57WC	Moderate	Decreased metabolism of Rasagiline caused by Tetrahydrozoline mediated inhibition of non-CYP450 enzyme.	Herpes simplex infection [1F00]	[39]
Maraviroc	DMTL94F	Moderate	Additive hypotensive effects by the combination of Rasagiline and Maraviroc.	Human immunodeficiency virus disease [1C60-1C62]	[30]
Teriflunomide	DMQ2FKJ	Moderate	Increased metabolism of Rasagiline caused by Teriflunomide mediated induction of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[32]
Aliskiren	DM1BV7W	Moderate	Additive hypotensive effects by the combination of Rasagiline and Aliskiren.	Hypertension [BA00-BA04]	[30]
Levamlodipine	DM92S6N	Moderate	Additive hypotensive effects by the combination of Rasagiline and Levamlodipine.	Hypertension [BA00-BA04]	[30]
TAK-491	DMCF6SX	Moderate	Additive hypotensive effects by the combination of Rasagiline and TAK-491.	Hypertension [BA00-BA04]	[30]
Clevidipine butyrate	DMW4M97	Moderate	Additive hypotensive effects by the combination of Rasagiline and Clevidipine butyrate.	Hypertension [BA00-BA04]	[30]
Givosiran	DM5PFIJ	Major	Decreased metabolism of Rasagiline caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[32]
Naphazoline	DMJFZDL	Moderate	Decreased metabolism of Rasagiline caused by Naphazoline mediated inhibition of non-CYP450 enzyme.	Itching [1F28-1G07]	[39]
Osimertinib	DMRJLAT	Moderate	Increased metabolism of Rasagiline caused by Osimertinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[40]
Capmatinib	DMYCXKL	Major	Decreased metabolism of Rasagiline caused by Capmatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[32]
Vemurafenib	DM62UG5	Major	Decreased metabolism of Rasagiline caused by Vemurafenib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[32]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Rasagiline and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[41]
Lasmiditan	DMXLVDT	Major	Additive serotonergic effects by the combination of Rasagiline and Lasmiditan.	Migraine [8A80]	[34]
Exjade	DMHPRWG	Major	Decreased metabolism of Rasagiline caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[32]
Ozanimod	DMT6AM2	Major	Decreased metabolism of Rasagiline caused by Ozanimod mediated inhibition of non-CYP450 enzyme.	Multiple sclerosis [8A40]	[42]
Dextroamphetamine	DMMIHVP	Moderate	Additive hypertensive effects by the combination of Rasagiline and Dextroamphetamine.	Narcolepsy [7A20]	[30]
Phendimetrazine	DM6TS1N	Moderate	Additive hypertensive effects by the combination of Rasagiline and Phendimetrazine.	Obesity [5B80-5B81]	[30]
Propylhexedrine	DMTBW2O	Moderate	Decreased metabolism of Rasagiline caused by Propylhexedrine mediated inhibition of non-CYP450 enzyme.	Obesity [5B80-5B81]	[39]
Lofexidine	DM1WXA6	Moderate	Additive hypotensive effects by the combination of Rasagiline and Lofexidine.	Opioid use disorder [6C43]	[30]
Rucaparib	DM9PVX8	Major	Decreased metabolism of Rasagiline caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[32]
Methamphetamine	DMPM4SK	Moderate	Additive hypertensive effects by the combination of Rasagiline and Methamphetamine.	Pain [MG30-MG3Z]	[43]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Rasagiline caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[44]
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Rasagiline and Silodosin.	Prostate hyperplasia [GA90]	[30]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Rasagiline and Levomepromazine.	Psychotic disorder [6A20-6A25]	[30]
Selexipag	DMAHSU0	Moderate	Additive hypotensive effects by the combination of Rasagiline and Selexipag.	Pulmonary hypertension [BB01]	[30]
Avanafil	DM75CXN	Moderate	Additive hypotensive effects by the combination of Rasagiline and Avanafil.	Sexual dysfunction [HA00-HA01]	[30]
Insulin degludec	DMPL395	Moderate	Increased risk of hypoglycemia by the combination of Rasagiline and Insulin degludec.	Type-1/2 diabete [5A10-5A11]	[45]
Xylometazoline	DMKV32D	Moderate	Decreased metabolism of Rasagiline caused by Xylometazoline mediated inhibition of non-CYP450 enzyme.	Vasomotor/allergic rhinitis [CA08]	[39]
-----------


⏷ Show the Full List of 48 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Carmellose sodium	E00625	Not Available	Disintegrant
Citric acid monohydrate	E00271	22230	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
--------------------


⏷ Show the Full List of 7 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Rasagiline 0.5 mg tablet	0.5 mg	Oral Tablet	Oral
Rasagiline 1 mg tablet	1 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6641).
2	Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54.
3	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
4	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
7	Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res. 2009 Aug;16(2):148-59.
8	Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. Am J Geriatr Pharmacother. 2006 Dec;4(4):330-46.
9	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
10	Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
11	Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
12	Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
13	PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
14	The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
15	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
16	The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
17	Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
18	Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
19	Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs. 2006 Sep;11(3):403-17.
20	Limitation of adipose tissue enlargement in rats chronically treated with semicarbazide-sensitive amine oxidase and monoamine oxidase inhibitors. Pharmacol Res. 2008 Jun;57(6):426-34.
21	Tranylcypromine: new perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):268-73.
22	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490).
23	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
24	Novel monoamine oxidase inhibitors, 3-(2-aminoethoxy)-1,2-benzisoxazole derivatives, and their differential reversibility. Jpn J Pharmacol. 2002 Feb;88(2):174-82.
25	Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells. Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H821-8.
26	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
27	Multiple mechanisms of action: the pharmacological profile of budipine. J Neural Transm Suppl. 1999;56:83-105.
28	Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
29	Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
30	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
31	Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5. [PMID: 4685619]
32	Cerner Multum, Inc. "Australian Product Information.".
33	Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology. J Allergy Clin Immunol 75 (1985): 443-9. [PMID: 2858503]
34	Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
35	Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL "Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings." J Clin Psychopharmacol 13 (1993): 312-20. [PMID: 8227489]
36	Graber MA, Hoehns TB, Perry PJ "Sertraline-phenelzine drug interaction: a serotonin syndrome reaction." Ann Pharmacother 28 (1994): 732-5. [PMID: 7919561]
37	Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62. [PMID: 14197995]
38	Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
39	Cusson JR, Goldenberg E, Larochelle P "Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans." J Clin Pharmacol 31 (1991): 462-7. [PMID: 2050833]
40	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
41	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
42	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
43	Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31. [PMID: 8845455]
44	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
45	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]